NCT04616859

Brief Summary

The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
32

participants targeted

Target at P25-P50 for not_applicable healthy

Timeline
Completed

Started Oct 2020

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 8, 2020

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

October 30, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 5, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 9, 2020

Status Verified

November 1, 2020

Enrollment Period

1.1 years

First QC Date

October 30, 2020

Last Update Submit

November 5, 2020

Conditions

Keywords

alcohol binge drinkingalcoholenergy drinkspharmacokineticscaffeinegender

Outcome Measures

Primary Outcomes (2)

  • Change in subjective effects measured with Biphasic alcohol effects scale (BAES)

    Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.

    From baseline to 8 hours after administration

  • Change in psychomotor vigilance task (PVT)

    Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

    From baseline to 6 hours after administration

Secondary Outcomes (26)

  • Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations

    From baseline to 8 hours after administration

  • Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations

    From baseline to 8 hours after administration

  • Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations

    From baseline to 8 hours after administration

  • Maximum concentration (Cmax) of ethanol in blood

    From baseline to 8 hours after administration

  • Maximum concentration (Cmax) of caffeine in plasma

    From baseline to 8 hours after administration

  • +21 more secondary outcomes

Study Arms (4)

Alcohol and Energy Drink (AmED)

EXPERIMENTAL

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml

Dietary Supplement: Alcohol and Energy Drink (AmED)

Alcohol and Energy drink Placebo

ACTIVE COMPARATOR

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)

Dietary Supplement: Alcohol and Energy drink Placebo

Alcohol placebo and Energy drink

ACTIVE COMPARATOR

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL

Dietary Supplement: Alcohol placebo and Energy drink

Alcohol placebo and Energy drink placebo

PLACEBO COMPARATOR

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total). Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL

Dietary Supplement: Alcohol placebo and energy drink placebo

Interventions

Multiple oral dose of alcohol mixed with ED

Alcohol and Energy Drink (AmED)

Multiple oral dose of alcohol mixed with ED placebo (soft drink)

Alcohol and Energy drink Placebo

Multiple oral dose of alcohol placebo (water) mixed with ED

Alcohol placebo and Energy drink

Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)

Alcohol placebo and Energy drink placebo

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.
  • Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week \[7 units, 70 g)\]) and having experienced drunkenness several times
  • Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.
  • Understand and accept the study's procedures and sign an informed consent form.
  • No evidence of somatic or psychiatric disorders as per past medical history and physical examination.
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

You may not qualify if:

  • Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.
  • Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.
  • Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.
  • Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  • Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.
  • Smokers of \>5 cigarettes/day
  • Consumption of \>20 g/day of alcohol (females) or of \>40 g/day (males)
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  • Subjects with positive serology to Hepatitis B, C or HIV.
  • Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).
  • Women with amenorrhea or suffering severe premenstrual syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)

Badalona, Barcelona, 08916, Spain

RECRUITING

Related Publications (1)

  • Hladun O, Papaseit E, Poyatos L, Martin S, Perez-Acevedo AP, Barriocanal AM, Bustos-Cardona T, Malumbres S, De La Torre R, Langohr K, Farre M, Perez-Mana C. No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode. Front Pharmacol. 2025 May 23;16:1581229. doi: 10.3389/fphar.2025.1581229. eCollection 2025.

MeSH Terms

Conditions

Alcohol DrinkingCoitus

Interventions

EthanolEnergy Drinks

Condition Hierarchy (Ancestors)

Drinking BehaviorBehaviorSexual Behavior

Intervention Hierarchy (Ancestors)

AlcoholsOrganic ChemicalsBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Clara Pérez-Mañá, MD, PhD

    Hospital Universitari Germans Trias i Pujol-IGTP

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clara Pérez-Mañá, MD,PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double-blind
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2020

First Posted

November 5, 2020

Study Start

October 8, 2020

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

November 9, 2020

Record last verified: 2020-11

Locations